---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-001712"
form_type: "8-K/A"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:42:02.666949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program

## Summary
- Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).
- Royalty payments from Takeda sublicense ~$2.5M, flat YoY; cash balance $6.2M at year-end.
- Entered Clinical Trial Services Agreement with PeriNess for DNase I studies in pancreatic, colorectal, and solid tumors.
- Extended collaborations with University of Virginia and Scripps Research through 2025.
- Progressing DNase I development program toward IND and first-in-human study for pancreatic carcinoma.

## SEC filing metadata
- accession: 0001683168-25-001712
- form_type: 8-K/A
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/0001683168-25-001712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/xenetic_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-001712
- JSON: https://secwatch.observer/filing/0001683168-25-001712.json
- Plain text: https://secwatch.observer/filing/0001683168-25-001712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.